New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, suggest good safety profile and continuous treatment effect of PXT3003 measured on the Overall ...
Applied Therapeutics, Inc. announced promising 18 and 24-month results from the INSPIRE Phase 2/3 trial of govorestat, a treatment for Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback